calcium carbonate and alphacalcidol

PreclinicalSmall molecule

calcium carbonate and alphacalcidol is one of 7 small molecule programs targeting Hypoparathyroidism. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypoparathyroidismActive, not recruiting

HypoparathyroidismPreclinical

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Hypoparathyroidism

#DrugCompanyPhaseTrials

Theo-Dur

Pfizer

Approved

2 2

Calciferol

Rocaltrol

Calcium

1 5

EXT608

EExtend Biosciences Inc.

Phase 2

1 6

Yorvipath

Ascendis Pharma

Preclinical

2 7

calcium carbonate and alphacalcidol

UUniversity of Athens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypoparathyroidism1 trial

Changes in Circulating Sclerostin Levels During Acute Postsurgical Hypoparathyroidism

Completed·UUniversity of Athens··NCT04146259·109 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for calcium carbonate and alphacalcidol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — calcium carbonate and alphacalcidol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for calcium carbonate and alphacalcidol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Athens company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Athens

calcium carbonate and alphacalcidol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypoparathyroidism1 trial

References

Drug Info

Quick Facts

Related News